secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clene Inc. (CLNN)
CIK:        0001822791
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0001437749-25-021483
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clene receives constructive FDA feedback on NfL biomarker analysis plan; ALS NDA on track for Q4 2025
--------------------------------------------------------------------------------

- FDA provided supportive feedback on Clene's statistical analysis plan for neurofilament light (NfL) biomarker analysis from NIH-sponsored Expanded Access Program.
- NfL analyses to be conducted early Q4 2025; may support accelerated approval NDA submission for CNM-Au8 in ALS.
- Two additional FDA meetings scheduled in Q3 2025: ALS survival data Type C and End-of-Phase 2 MS program Type B.
- NDA submission under accelerated approval pathway remains on track for potential submission in Q4 2025.
- EAP supports nearly 200 ALS patients treated with compassionate use CNM-Au8; comparator group uses matched controls.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822791/000143774925021483/0001437749-25-021483-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822791/000143774925021483/clnn20250627_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-021483

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer